ESR1 and breast carcinoma: The role of immunohistochemistry (IHC) within this arena is most likely to involve predictive biomarker development, as highlighted by the classical success of both estrogen receptor (ER) and Her2 in breast cancer, which predict response to tamoxifen and trastuzumab, respectively.